SVRA
Savara, Inc.
$5.59
+1.82%
2026-08-21
About Savara, Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Key Fundamentals
Forward P/E
-17.24
EPS (TTM)
$-0.58
ROE
-105.5%
Profit Margin
0.0%
Debt/Equity
21.17
Price/Book
7.75
Beta
0.26
Market Cap
$1.11B
Avg Volume (10D)
1.4M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$6.47
60D Low
$4.73
Avg Volume
1.8M
Latest Close
$5.59
Get breakout alerts for SVRA
Sign up for Breakout Scanner to receive daily notifications when SVRA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Savara, Inc. (SVRA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SVRA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SVRA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.